Today, we revisit biopharma concern Supernus Pharmaceuticals whose just reported 4th quarter results that triggered a near 10% selloff in its stock.
However, the company reported solid results for the quarter and year and navigated the impacts of the pandemic quite well in 2020.
Investors seem to be overlooking the potential FDA approval of another drug for the company's pipeline in 2021 as well as a huge cash hoard on its balance sheet.
We update our investment analysis on Supernus Pharmaceuticals in the paragraphs that follow.
READ FULL ARTICLE HERE
